Standard BioTools Inc. (NASDAQ: LAB) announced on November 19, 2026, that its stockholders have approved all proposals related to the company’s planned merger with Treeline Biosciences, Inc., as well as the divestiture of its Mass Cytometry business.
The approvals were decided at a virtual Special Meeting of Stockholders held on November 19, 2026. At the close of business on October 16, 2026, there were 394,711,296 shares of common stock issued and outstanding. A total of 281,744,412 votes, representing approximately 71.38% of the voting power, were cast at the meeting.
The following proposals were approved by the stockholders:
- Share Issuance Proposal: Approved to issue shares of Common Stock in connection with the Merger, in accordance with Nasdaq Listing Rules.
- Charter Amendment Proposal: Approved to amend the company’s certificate of incorporation to effect a reverse stock split ranging from 1-for-20 to 1-for-40 and to change the company’s name to “Treeline Biosciences, Inc.”
- Post-Closing Equity Incentive Plan Proposal: Approved to establish a new equity incentive plan that will become effective upon the closing of the Merger.
- Post-Closing ESPP Proposal: Approved to establish a new Employee Stock Purchase Plan that will become effective upon the closing of the Merger.
- Advisory Compensation Proposal: Approved on a nonbinding basis the Transaction-Related Compensation.
- Element Mass Cytometry Divestiture Proposal: Approved the sale of the Mass Cytometry business to Element Biosystems, LLC.
- Adjournment Proposal: Approved the ability to adjourn the Special Meeting if necessary to secure additional votes.
The merger with Treeline is expected to close in the fourth quarter of 2026, subject to the satisfaction of customary closing conditions. The sale of the Mass Cytometry business is anticipated to close substantially concurrently with the merger.